

# Balaxi Pharmaceuticals Limited

Date: 05.08.2025

To,  
Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

**NSE Symbol: BALAXI**

Dear Sir/Madam,

**Subject: Outcome of Board Meeting**

In reference to our letter dated July 29,2025, we wish to inform you that the Board of Directors at their meeting held today i.e., August 05,2025, have *inter-alia*, approved the following:

**1. Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2025.**

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2025, accompanied by Limited Review Report thereon by the Statutory Auditors of the Company as **Annexure A.**

**2. Took note of the update on the Company's first Pharmaceutical Formulation plant at Jadcherla, Hyderabad**

The Managing Director apprised the Board of Directors on the progress of the Company's first formulation plant at Jadcherla, Hyderabad.

He mentioned that installation qualification (IQ),Operational Qualification (OQ) and Performance Qualification (PQ) for all plant and machinery have successfully been completed.

Water validation and vendor qualification process are underway and expected to conclude by end of August,2025.

Further, he mentioned that the manufacturing test licence has been obtained from the authority and the commencement of the stability batch production is expected to start from early September, 2025.

The Board meeting commenced at 11.10 a.m. (IST) and concluded at 2.30 p.m. (IST).

**Registered Office:**

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

# Balaxi Pharmaceuticals Limited

The aforesaid information is also being hosted on the Company's website at [www.balaxipharma.in](http://www.balaxipharma.in).

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

**Mohith Kumar Khandelwal**

*(Company Secretary and Compliance Officer)*

*Membership No.: F11243*

**Registered Office:**

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: [info@balaxi.in](mailto:info@balaxi.in) | Website: [www.balaxipharma.in](http://www.balaxipharma.in)

# Balaxi Pharmaceuticals Limited

2nd Floor, MAPS Towers, Plot no. 409, Road no. 81, Jubilee Hills, Phase III, Hyderabad-500096, Telangana  
CIN:L25191TG1942PLC121598

## Unaudited Financial Results for the Quarter Ended 30th June, 2025

Particulars	Quarter Ended			Year Ended
	30.06.2025	31.03.2025	30.06.2024	31.03.2025
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>Income</b>				
Revenue from operations	1,670.82	964.89	1,902.58	6,098.82
Other income	46.22	32.09	84.50	537.34
<b>Total Income</b>	<b>1,717.04</b>	<b>996.98</b>	<b>1,987.08</b>	<b>6,636.16</b>
<b>Expenses</b>				
Cost of Goods Sold	1,417.59	822.09	1,569.48	5,094.16
Employee benefit expense	131.35	134.24	114.91	487.14
Finance cost	63.10	69.33	35.36	205.77
Depreciation and amortisation expense	11.28	11.15	11.52	45.60
Administrative expenses	67.89	73.92	67.08	274.72
<b>Total Expenses</b>	<b>1,691.21</b>	<b>1,110.73</b>	<b>1,798.35</b>	<b>6,107.38</b>
<b>Profit/(loss) before tax and other comprehensive income</b>	<b>25.83</b>	<b>(113.75)</b>	<b>188.73</b>	<b>528.78</b>
<b>Tax expenses</b>				
Current tax	8.12	7.99	53.03	178.20
Deferred tax	(1.78)	(3.89)	(1.93)	(9.56)
<b>Net Profit/(loss) for the period</b>	<b>19.49</b>	<b>(117.85)</b>	<b>137.63</b>	<b>360.14</b>
<b>Other comprehensive income</b>				
A (i) Items that will not be reclassified to profit or loss in subsequent period	-	-	-	-
Re-measured gains on defined benefit plans	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>Total comprehensive income for the year</b>	<b>19.49</b>	<b>(117.85)</b>	<b>137.63</b>	<b>360.14</b>
Paid up equity share capital - Face value of Rs.2 each	1,104.15	1,104.15	1,104.15	1,104.15
Other Equity				
<b>Earnings Per Share (EPS)</b>				
(EPS for the quarter is not annualised)				
-Basic (Amount in Rs.)	0.04	(0.21)	0.25	0.65
-Diluted (Amount in Rs.)	0.04	(0.21)	0.25	0.65

### Notes :

- The Unaudited Financial Results for the Quarter ended 30th June , 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 5th August, 2025. The Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The Financial Results were reviewed by the statutory auditors and limited review report was given thereon.
- Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification.
- The operating segment of the Group is identified as "Specialized Wholesale" as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, the disclosure as per Regulation 33 (1)(e) read with Clause L of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company.



For and on behalf of Board of Directors  
of Balaxi Pharmaceuticals Limited

*(Signature)*  
Ashish Maheshwari  
Managing Director  
DIN: 01575984

Place: Hyderabad  
Date: 5th August, 2025

# Balaxi Pharmaceuticals Limited

2nd Floor, MAPS Towers, Plot no. 409, Road no. 81, Jubilee Hills, Phase III, Hyderabad-500096, Telangana  
CIN:L25191TG1942PLC121598

## Unaudited Consolidated Financial Results for the Quarter Ended 30th June, 2025

Particulars	Quarter Ended			(Rs. in Lakhs)
	30.06.2025	31.3.2025	30.6.2024	31.03.2025
	Unaudited	(Audited)	Unaudited	(Audited)
<b>Income</b>				
Revenue from operations	7,074.21	7,626.61	6,562.15	29,256.12
Other income	(177.66)	(169.34)	(184.79)	(371.64)
<b>Total Income</b>	<b>6,896.55</b>	<b>7,457.27</b>	<b>6,377.36</b>	<b>28,884.48</b>
<b>Expenses</b>				
Cost of Goods Sold	3,955.99	3,955.71	3,813.67	16,570.09
Employee benefit expense	841.23	889.32	810.29	3,473.96
Finance cost	100.61	73.56	37.08	293.46
Depreciation and amortisation expense	46.25	46.10	49.21	189.46
Administrative Expenses	1,862.15	1,526.32	929.62	5,490.55
<b>Total Expenses</b>	<b>6,806.21</b>	<b>6,491.00</b>	<b>5,639.87</b>	<b>26,017.52</b>
<b>Profit/(Loss) Before Exceptional Item</b>	<b>90.34</b>	<b>966.27</b>	<b>737.49</b>	<b>2,866.96</b>
Exceptional Item	-			
<b>Profit/(loss) before tax and other comprehensive income</b>	<b>90.34</b>	<b>966.27</b>	<b>737.49</b>	<b>2,866.96</b>
<b>Tax expenses</b>				
Current tax	63.11	106.38	91.38	369.50
Deferred tax	(1.78)	(3.87)	(1.93)	(9.56)
<b>Net Profit/(loss) for the period</b>	<b>29.01</b>	<b>863.76</b>	<b>648.04</b>	<b>2,507.02</b>
<b>Other comprehensive income</b>				
A (i) Items that will not be reclassified to profit or loss in subsequent period				
Exchange differences on translation of foreign operations	108.27	(41.91)	4.14	259.78
(ii) Income tax relating to items that will not be reclassified to profit or loss				
B (i) Items that will be reclassified to profit or loss		-		
(ii) Income tax relating to items that will be reclassified to profit or loss		-		
<b>Total comprehensive income for the year</b>	<b>137.28</b>	<b>821.85</b>	<b>652.18</b>	<b>2,766.80</b>
Paid up equity share capital - Face value of Rs.2 each	1,104.15	1,104.15	1,104.15	1,104.15
Other Equity				
<b>Earnings Per Share (EPS)</b>				
(EPS for the quarter is not annualised)				
-Basic (Amount in Rs.)	0.05	1.56	1.17	4.54
-Diluted (Amount in Rs.)	0.05	1.56	1.17	4.54

### Notes :

- The Unaudited Consolidated Financial Results for the Quarter and Year ended 30th June , 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 5th August, 2025. The Consolidated Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The Financial Results were reviewed by the statutory auditors and limited review report was given thereon
- Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period's classification.
- The operating segment of the Group is identified as "Specialized Wholesale" as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, the disclosure as per Regulation 33 (1)(e) read with Clause L of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company.
- During this quarter under review, the company's wholly-owned subsidiary Balaxi Global DMCC, Dubai acquired 100% stake in Balaxi Healthcare Nicaragua.



For and on behalf of Board of Directors  
of Balaxi Pharmaceuticals Limited

*(Signature)*  
Ashish Maheshwari  
Managing Director  
DIN: 01575984

Place: Hyderabad  
Date: 5th August, 2025





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com

Website : www.pmurali.com


**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review report to  
The Board of Directors  
Balaxi Pharmaceuticals Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **BALAXI PHARMACEUTICALS LIMITED** (the "Company") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com


Website : www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.

Chartered Accountants

FRN: 007257S



A. Krishna Rao

Partner

M.No. 020085

UDIN: 25020085BMILJK4850.

Place: Hyderabad

Date: 05-08-2025





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review report to  
The Board of Directors  
Balaxi Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of **BALAXI PHARMACEUTICALS LIMITED** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRI) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032


Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com  
Website : www.p murali.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- i. M/s. Balaxi Global DMCC, Dubai (Wholly owned subsidiary) which includes following wholly owned Subsidiaries:
  - 1 Balaxi Healthcare Guatemala, S.A, Dominican Republic(wholly owned subsidiary of Balaxi Global DMCC, Dubai)
  - 2 Balaxi Healthcare Dominican, S.R.L, Dominican Republic(wholly owned subsidiary of Balaxi Global DMCC, Dubai)
  - 3 Balaxi Healthcare, Honduras, S DE RL DE CV(wholly owned subsidiary of Balaxi Global DMCC, Dubai)
  - 4 Balaxi Healthcare El Salvador SA DE (wholly owned subsidiary of Balaxi Global DMCC, Dubai)
  - 5 Balaxi Healthcare Angola(wholly owned subsidiary of Balaxi Global DMCC, Dubai)
  - 6 Balaxi Healthcare Nicaragua (wholly-owned subsidiary of Balaxi Global DMCC, Dubai.)
- ii. M/s. Balaxi Healthcare Ecuador S.A.S. (Wholly owned subsidiary)

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.







**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com

Website : www.pmurali.com

The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:

Two wholly owned subsidiaries, whose interim financial results and other financial information reflect total revenues of Rs. 6850.33 Lakhs, total net profit after tax of Rs.7.82 Lakhs and comprehensive income of Rs. 76.37 Lakhs for the quarter ended June 30,2025, as considered in the Statement whose interim financial results and other financial information have not been reviewed by their auditors;

These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information.

Our conclusion on the Statement in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management

For P. Murali & Co.

Chartered Accountants

FRN: 0072579

A. Krishna Rao

Partner

M. No. 020085

UDIN: 25020085BMILJL3301

Place: Hyderabad

Date: 05-08-2025